Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

ExxonMobil mulls sale of European chemical plants - report

(Sharecast News) -

ExxonMobil is reportedly seeking to offload European chemical plants as the sector reels from US tariffs and increased competition from China.

The US energy producer held talks with advisers in recent weeks on possible sales, which could fetch up to $1bn, the Financial Times reported on Thursday, citing unnamed sources.

Other chemicals companies are also trying to engineer exits from their European operations, as the continent has borne the brunt of the downturn. Earlier this year, LyondellBasell sold four European plants, while Saudi Arabia's Sabic is considering a similar change.

ExxonMobil owns an ethylene plant in the Scottish town of Fife, as well as several production sites in Belgium. It had also discussed simply shutting them down, the sources said, adding there was no guarantee a deal would materialise, and the firm could opt to hold on to the assets. The company told the newspaper did not "comment on rumours or speculation".

The European chemicals industry is facing renewed pressure as US tariffs disrupt global trade, delay orders, and intensify competition from low-cost Chinese rivals, threatening recovery in a sector still reeling from the 2022 energy crisis.

Exxon in May said it was in exclusive talks to sell its controlling stake in French fuel subsidiary Esso SAF, as well as its wholly owned chemical business in the country to North Atlantic France SAS, a division of the Canadian fuel retailer North Atlantic.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.